Comments on "Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study"

Crit Care. 2024 Dec 20;28(1):428. doi: 10.1186/s13054-024-05187-5.

Rong Li^{1

2}, JuanJuan Wang¹, Qian Li¹, QianYue Guo¹, Jun Kang Zhao¹, James Cheng-Chung Wei^{3

4

5}, Li-Yun Zhang^{6

7}

¹ Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
² Shanxi Province Clinical Theranostics Technology Innovation Center for Immunologic and Rheumatic Diseases, Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases (Rheumatic diseases), Taiyuan, China.
³ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. jccwei@gmail.com.
⁴ Department of Allergy, Chung Shan Medical University Hospital, Immunology & Rheumatology, Taichung, Taiwan. jccwei@gmail.com.
⁵ Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. jccwei@gmail.com.
⁶ Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China. zhangly@sxbqeh.com.cn.
⁷ Shanxi Province Clinical Theranostics Technology Innovation Center for Immunologic and Rheumatic Diseases, Shanxi Province Clinical Research Center for Dermatologic and Immunologic Diseases (Rheumatic diseases), Taiyuan, China. zhangly@sxbqeh.com.cn.

No abstract available

Publication types